Clinical Trial Update: A Trial Investigating the Pharmacokinetic (Mode of Action in the Body) and Safety Profiles of NN1250 (Insulin Degludec) in Subjects With Various Degrees of Impaired Liver Function and in Subjects With Normal Liver Function [Phase 1]

View source ↗

Summary

Phase 1 study assessing pharmacokinetics and safety of NN1250 (insulin degludec) in subjects with varying liver function, including normal liver function; study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus

Drugs mentioned

• NN1250 (insulin degludec) (insulin degludec)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes, Healthy | Phase 1 | Status: COMPLETED